Ainos (AIMD) AI Stock Analysis

• Market Cap: $10.90M
• Dividend Yield: N/A
• Average Volume (3M): 76.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: 13.38%
• EPS Growth: 57.99%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.04
• Shares Outstanding: 4,192,041
• 10 Day Avg. Volume: 86,017
• 30 Day Avg. Volume: 76,276
• PEG Ratio: -0.16
• Price to Book (P/B): 3.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.16
• Enterprise Value/Market Cap: 1.96
• Enterprise Value/Revenue: 91.80
• Enterprise Value/Gross Profit: 343.79
• Enterprise Value/Ebitda: -0.50
• 1Y Price Target: $0.50
• Price Target Upside: -80.77% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: $3.00 ▲(15.38%Upside)

Ainos' overall stock score is weighted heavily by its poor financial performance and challenging valuation, which highlight the company's current operational and financial struggles. However, the positive corporate events and stable technical indicators offer some potential for future improvement, balancing the overall outlook.

Ainos Business Overview & Revenue Model

Company Description

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.

How the Company Makes Money

Ainos generates revenue through the sale and licensing of its proprietary medical technologies and products. The company earns money by developing diagnostic tools and therapeutic solutions that are sold directly to healthcare providers and institutions. Additionally, Ainos may enter into strategic partnerships and collaborations with other biotechnology firms to co-develop and commercialize new products, thereby creating additional revenue streams through licensing agreements, royalties, and joint ventures.

Ainos Financial Statement Overview

Summary

Ainos faces severe financial challenges, including a decline in revenue to zero, persistent losses, negative cash flows, high leverage, and operational inefficiencies. Despite slight improvements in equity, the financial health is weak, necessitating urgent strategic adjustments.

Income Statement

Ainos has experienced a severe decline in revenue over the years, with Total Revenue dropping to zero in the most recent year. This, coupled with negative gross and net profit margins, indicates significant operational challenges and profitability issues. There is also a lack of revenue growth, as recent results reflect a substantial decrease from previous years.

Balance Sheet

Ainos has a high debt-to-equity ratio, indicating leveraged financial structure, but the equity position has improved from negative to positive over time. However, the equity ratio remains relatively low, reflecting limited financial stability. Return on Equity is negative due to ongoing losses, suggesting inefficiencies in generating returns on shareholder investment.

Cash Flow

The company's cash flow metrics reveal persistent negative operating and free cash flows, highlighting liquidity challenges. Despite some improvements in financing activities, operating cash flow remains significantly negative compared to net income, indicating operational inefficiencies and cash flow constraints.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.73K	122.11K	3.52M	594.56K	16.56K
Gross Profit	-31.87K	-253.73K	1.41M	410.38K	5.29K
EBITDA	-9.44M	-8.77M	-9.14M	-1.84M	-1.43M
Net Income	-14.86M	-13.77M	-14.01M	-3.89M	-1.45M
Balance Sheet
Total Assets	28.82M	31.84M	37.11M	40.82M	260.29K
Cash, Cash Equivalents and Short-Term Investments	3.89M	1.89M	1.85M	1.75M	22.25K
Total Debt	12.00M	5.96M	1.27M	3.62M	953.00K
Total Liabilities	13.30M	7.39M	2.48M	30.63M	1.10M
Stockholders Equity	15.52M	24.45M	34.63M	10.20M	-838.28K
Cash Flow
Free Cash Flow	-5.83M	-4.79M	-3.66M	-1.39M	-506.79K
Operating Cash Flow	-5.81M	-4.69M	-3.02M	-1.25M	-499.55K
Investing Cash Flow	-125.29K	-101.53K	-630.18K	-180.52K	-7.24K
Financing Cash Flow	8.03M	4.92M	3.83M	3.15M	120.00K

Ainos Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIMD, the sentiment is Negative. The current price of 2.6 is below the 20-day moving average (MA) of 2.87, below the 50-day MA of 2.85, and below the 200-day MA of 2.73, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 40.85 is Neutral, neither overbought nor oversold. The STOCH value of 23.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIMD.

Ainos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KPRX	56 Neutral	$9.28M	4.67	-41.13%	―	―	―
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
AIMD	52 Neutral	$10.90M	―	-82.87%	―	13.38%	57.99%
EVAX	48 Neutral	$3.80M	―	-205.75%	―	2552.29%	60.70%
IBIO	42 Neutral	$12.00M	―	-90.83%	―	650.00%	89.72%
APRE	40 Underperform	$10.68M	―	-59.80%	―	157.63%	40.52%
ACXP	39 Underperform	$13.10M	―	-285.79%	―	―	23.65%

Ainos Corporate Events

Ainos Regains Nasdaq Compliance, Eyes AI Expansion

On July 16, 2025, Ainos, Inc. announced that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement, marking a significant milestone for the company. This achievement coincides with Ainos’ strategic efforts to expand its AI Nose platform, which includes partnerships with major companies like ASE Technology Holding and Kenmec, and aims for large-scale commercialization by 2026. The company has outlined a 90-day roadmap to enhance its market presence, focusing on deploying AI Nose units, showcasing integrated technology at industry events, and pursuing new partnerships in Asia and Europe.

Ainos Partners with Kenmec for AI Integration

On June 24, 2025, Ainos, Inc. announced a strategic partnership with Kenmec Mechanical Engineering Co., Ltd., a leader in automation and system integration. This collaboration aims to integrate Ainos’ AI Nose and smell language model technologies into Kenmec’s smart factory ecosystem, enhancing environmental awareness and anomaly detection in unmanned environments. This partnership marks a significant step in Ainos’ international expansion, following successful implementations in Japan’s eldercare and semiconductor sectors. By combining AI Nose with Kenmec’s platforms, the partnership seeks to redefine industrial perception and capitalize on the growing demand for intelligent environmental sensing.